2020 Year in Review: Non–Small-Cell Lung Cancer

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.

Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.

First-line treatment with osimertinib in patients with EGFR-mutated is associated with longer overall survival compared with other drugs in its class.

Researchers presented updated 5-year progression-free survival and overall survival data from a clinical trial evaluating the efficacy and safety of alectinib versus crizotinib in previously untreated patients with ALK-positive NSCLC.

Treatment with combination apatinib and gefitinib is associated with improved progression-free survival compared with treatment with gefitinib alone in patients with NSCLC and EGFR mutations.

A phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan shows potential for treating patients with EGFR-mutated NSCLC.

Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation.

Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC.

The open-label, phase 2 VISION study evaluated the efficacy and safety of tepotinib, a highly selective oral MET inhibitor, in patients with advanced NSCLC with MET alterations.

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC.